ArticleJAMA network open2026
Randomized Clinical Trials Using a Hierarchical Composite Primary End Point: A Scoping Review.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Hierarchical composite end points (HCEs) are a promising tool used in randomized clinical trials (RCTs) to integrate multiple outcomes of varying clinical relevance into a single measure. Objective: To describe how often HCEs are used as primary outcomes in RCTs, and how they are constructed, analyzed, and reported. Evidence Review: MEDLINE, Embase, CENTRAL, and Web of Science were searched on December 9, 2024, complemented by a forward citation search of methodological papers on HCEs. RCTs that used an HCE as their primary outcome were included, defined either by self-declaration (hierarchical composite or outcome ranking) or through use of an HCE-specific analytical approach (win ratio, win odds, probabilistic index, or generalized pairwise comparison). Pilot studies, post hoc analyses, and hierarchically tested coprimary end points were excluded. Data were independently screened and extracted in duplicate. Trial characteristics, end point composition, hierarchy justification, and analytical methods were summarized descriptively. Findings: Among 5188 screened records, 92 RCTs were included, with 79 567 planned participants. The use of an HCE as a primary end point has increased, with 72 trials (78.3%) initiating recruitment within the past decade. Most RCTs were drug trials (43.5% [40 of 92]), in cardiology (43.5% [40 of 92]), multicenter (91.3% [84 of 92]), and non-industry sponsored (67.4% [62 of 92]). The 92 HCEs had a median (IQR) of 4 (3-5) components and the highest ranked component was usually mortality (80.4% [74 of 92]). The last hierarchical component was most often a continuous component (64.1% [59 of 92]). The majority of RCTs did not report any information on how the hierarchy was established (82.2% [60 of 73]; excluding RCTs where only information from registries was available). Generalized pairwise comparison was the most frequent analysis approach (57.3% [26 of 45]) among the 45 published RCTs, yet no standardized way for presenting results was observed. Conclusions and Relevance: This scoping systematic review of 92 RCTs using HCEs found that their use has increased across medical fields, but their construction, analytical approaches, and reporting of results remained highly heterogeneous. By systematically mapping how HCEs are currently implemented, further review is essential for the development of much needed methodological and reporting standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.